Search results for "610 Medicine & health"

showing 10 items of 627 documents

Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.

2021

BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying aetiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease aetiology and baseline serum viral load. METHODS Meta-analysis was conducted in patients with aHCC and alpha-fetoprotein (AFP) ≥400 ng/mL (N = 542) from REACH/REACH-2 trials. Individual patient-level data were pooled with results reported by aetiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pre-treatment serum HBV DNA and HCV RNA were quantified using Roche CO…

medicine.medical_specialtyCarcinoma Hepatocellular610 Medizin610 Medicine & healthChronic liver diseaseAntibodies Monoclonal HumanizedGastroenterologyRamucirumab03 medical and health sciencesLiver disease0302 clinical medicine610 Medical sciencesInternal medicineMedicineHumans030304 developmental biology0303 health sciencesHepatologybusiness.industryLiver NeoplasmsHepatitis CHepatitis Bmedicine.diseasedigestive system diseases3. Good healthClinical Trials Phase III as Topic030220 oncology & carcinogenesisHepatocellular carcinomaLiver functionbusinessViral load
researchProduct

Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee o…

2020

The aims of this paper were to provide an overview of available activity monitors used in research in patients with heart failure and to identify the key criteria in the selection of the most appropriate activity monitor for collecting, reporting, and analysing physical activity in heart failure research. This study was conducted in three parts. First, the literature was systematically reviewed to identify physical activity concepts and activity monitors used in heart failure research. Second, an additional scoping literature search for validation of these activity monitors was conducted. Third, the most appropriate criteria in the selection of activity monitors were identified. Nine activi…

medicine.medical_specialtyCardiologyPhysical activity610 Medicine & healthHeart failureFitness Trackers030204 cardiovascular system & hematologyMedical and Health Sciences2705 Cardiology and Cardiovascular MedicineExercise Capacity03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansCardiac and Cardiovascular SystemsIn patientExercise physiologyAssociation (psychology)Set (psychology)ExerciseMonitoring PhysiologicHeart FailureKardiologiPhysical activitybusiness.industryPhysical activity; Activity monitor; Motion sensor; Accelerometer; Heart failuremedicine.diseaseActivity monitor[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAccelerometerHeart failure10209 Clinic for CardiologyMotion sensorPosition paperPosition PaperHuman medicineClinical MedicineCardiology and Cardiovascular MedicineRaw databusinessEuropean Journal of Heart Failure
researchProduct

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

2009

Abstract Objective : Subjects with rheumatoid arthritis (RA) have increased cardiovascular risk and may show atherogenic forms of dyslipidemia. The present study investigated whether patients with early RA, beyond alterations in plasma lipids, also show lower LDL size and altered LDL subclass distribution. Design and Methods We identified 25 subjects with RA (47±8 years, body mass index (BMI) 25±4kg/m 2 ) by the American College of Rheumatology diagnostic criteria, with a disease durations Results As compared to controls RA patients had higher plasma triglycerides (1.8±0.5 vs. 1.0±0.5mmol/L, p p =0.0027), while total- and LDL-cholesterol concentrations were similar. LDL particle size was lo…

medicine.medical_specialtyCholesterolbusiness.industry10265 Clinic for Endocrinology and DiabetologyArthritisBlood lipids610 Medicine & healthRheumatoid arthritis small dense LDL HDL-cholesterol Triglyceridesmedicine.disease2705 Cardiology and Cardiovascular MedicineRheumatologychemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineRheumatoid arthritisLow-density lipoproteinmedicineCardiology and Cardiovascular MedicinebusinessaterosclerosiDyslipidemia
researchProduct

Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis.

2020

Highlights • Acute pulmonary embolism (PE) is a frequent complication of COVID-19 infection. • The in-hospital incidence of acute PE among COVID-19 patients is higher in ICU patients. • Computed tomography angiography (CTPA) is infrequently performed.

medicine.medical_specialtyComputed Tomography AngiographyEpidemiology610 Medicine & healthReview Article030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicinemedicineInternal MedicineHumans030212 general & internal medicineCOVIDLungbusiness.industry10031 Clinic for AngiologyIncidenceIncidence (epidemiology)Pulmonary embolismmedicine.diseaseThrombosisIntensive care unitConfidence intervalPulmonary embolismHospitalizationIntensive Care UnitsMeta-analysismedicine.anatomical_structure2724 Internal MedicineMeta-analysisAcute DiseaseComplicationbusinessCovid-19European Journal of Internal Medicine
researchProduct

The Valencia consensus-based adaptation of the IASP complex regional pain syndrome diagnostic criteria

2021

Refereed/Peer-reviewed The new IASP diagnostic criteria for complex regional pain syndrome (CRPS) (aka “the Budapest Criteria”3; Table 1) have improved the diagnostic specificity for CRPS while maintaining good sensitivity. Internationally, these criteria are now in common use. The IASP CRPS Special Interest Group convened a workshop of CRPS experts in Valencia/Spain in September 2019 to review perceived ambiguities in the diagnostic text and issues identified in applying these criteria in both the research and clinical contexts. After this review, workshop attendees discussed and reached a consensus regarding adaptations to the diagnostic taxonomy text. This process resulted in pragmatic u…

medicine.medical_specialtyConsensusMEDLINEComplex Regional Pain Syndromes/diagnosis610 Medicine & healthWorld Health OrganizationDiagnosis DifferentialPhysical medicine and rehabilitationInternational Classification of DiseasesMedicineHumansIASP diagnostic criteriaAdaptation (computer science)complex regional pain syndrome (CRPS)business.industrymedicine.diseaseAnesthesiology and Pain MedicineComplex regional pain syndrome2728 Neurology (clinical)Neurology2808 NeurologyPerspective10046 Balgrist University Hospital Swiss Spinal Cord Injury CenterNeurology (clinical)2703 Anesthesiology and Pain MedicineChronic PainbusinessComplex Regional Pain Syndromes
researchProduct

Minimal Reporting Standards for Active Middle Ear Hearing Implants.

2017

There is currently no standardized method for reporting audiological, surgical and subjective outcome measures in clinical trials with active middle ear implants (AMEIs). It is often difficult to compare studies due to data incompatibility and to perform meta-analyses across different centres is almost impossible. A committee of ENT and audiological experts from Germany, Austria and Switzerland decided to address this issue by developing new minimal standards for reporting the outcomes of AMEI clinical trials. The consensus presented here aims to provide a recommendation to enable better inter-study comparability.

medicine.medical_specialtyConsensusPhysiologyHearing lossHearing Loss Sensorineural610 Medicine & healthAudiology03 medical and health sciencesSpeech and Hearing0302 clinical medicineHearing AidsHearingGermanyOutcome Assessment Health CaremedicineHumans610 Medicine & health030223 otorhinolaryngologyOriginal Paperbusiness.industryHearing TestsComparabilityOutcome measuresAudiogramSensory SystemsClinical trialOssicular Prosthesismedicine.anatomical_structureTreatment OutcomeOtorhinolaryngologyHearing resultsMeta-analysisAustriaMiddle earmedicine.symptombusiness030217 neurology & neurosurgerySwitzerlandAudiologyneuro-otology
researchProduct

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

2015

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 EpidemiologyEuropean Journal of Preventive Cardiology
researchProduct

Thrombosis and thromboembolism related to COVID‐19: A clarion call for obtaining solid estimates from large‐scale multicenter data

2020

Abstract The clinical spectrum of coronavirus disease 2019 (COVID‐19) is wide, ranging from minor, nonspecific symptoms to severe pneumonia, acute respiratory distress syndrome, multiorgan involvement, and shock. In severe cases, the acute systemic inflammatory response, coagulation activation, and diffuse endothelial damage may, in combination with hypoxia, immobilization, and underlying risk factors, result in potentially life‐threatening venous and arterial thrombotic events. The first data from single‐center retrospective studies suggest that thrombotic events are a key aspect of COVID‐19‐associated morbidity and mortality. We have planned and will be launching the COvid REgistry on THR…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Hospitalized patientsvenous thromboembolism610 Medicine & healthAcute respiratory distressregistrymedicine.disease_causeSARS‐CoV‐2COVID‐19Internal medicineMedicineIn patientthrombosisCoronavirusCOVIDbusiness.industryForumlcsh:RC633-647.510031 Clinic for AngiologyRetrospective cohort studyHematologylcsh:Diseases of the blood and blood-forming organsHypoxia (medical)medicine.diseaseThrombosismedicine.symptombusinessResearch and Practice in Thrombosis and Haemostasis
researchProduct

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct